BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15777262)

  • 1. Transglutaminases as targets for pharmacological inhibition.
    Wodzinska JM
    Mini Rev Med Chem; 2005 Mar; 5(3):279-92. PubMed ID: 15777262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminases in disease.
    Kim SY; Jeitner TM; Steinert PM
    Neurochem Int; 2002 Jan; 40(1):85-103. PubMed ID: 11738475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transglutaminases - possible drug targets in human diseases.
    Gentile V; Cooper AJ
    Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
    Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
    Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminase inhibitors: a patent review.
    Keillor JW; Apperley KY
    Expert Opin Ther Pat; 2016; 26(1):49-63. PubMed ID: 26560530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminases: nature's biological glues.
    Griffin M; Casadio R; Bergamini CM
    Biochem J; 2002 Dec; 368(Pt 2):377-96. PubMed ID: 12366374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
    Siegel M; Khosla C
    Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New target against inflammatory diseases: transglutaminase 2.
    Kim SY
    Arch Immunol Ther Exp (Warsz); 2004; 52(5):332-7. PubMed ID: 15507874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multifaceted role of transglutaminase in neurodegeneration: review article.
    Karpuj M; Steinman L
    Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced transglutaminase-catalyzed protein aggregation is observed in the presence of creatine using sedimentation velocity.
    Burguera EF; Love BJ
    Anal Biochem; 2006 Mar; 350(1):113-9. PubMed ID: 16445883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration.
    Citron BA; Suo Z; SantaCruz K; Davies PJ; Qin F; Festoff BW
    Neurochem Int; 2002 Jan; 40(1):69-78. PubMed ID: 11738473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?
    Cooper AJ; Jeitner TM; Gentile V; Blass JP
    Neurochem Int; 2002 Jan; 40(1):53-67. PubMed ID: 11738472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transglutaminase and neurodegenerative diseases].
    Liu Z; Zeng J; Zeng S; Tang B; Wang J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
    Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
    Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver.
    Elli L; Bergamini CM; Bardella MT; Schuppan D
    Dig Liver Dis; 2009 Aug; 41(8):541-50. PubMed ID: 19195940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
    Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assays for transglutaminases in cell death.
    Melino G; Candi E; Steinert PM
    Methods Enzymol; 2000; 322():433-72. PubMed ID: 10914039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminases in vascular biology: relevance for vascular remodeling and atherosclerosis.
    Bakker EN; Pistea A; VanBavel E
    J Vasc Res; 2008; 45(4):271-8. PubMed ID: 18212504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.